Biogen

BYOOVIZ

ASP | WAC | AWP at the HCPCS Unit

Manufacturer:

Biogen

Byooviz HCPCS:

Q5124

HCPCS Code Descriptor:

Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg

Category:

Q Code

Byooviz NDCs:

64406-0019-01

Primary Type:

Opthalmic Biosimilar

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intraocular

Byooviz CPT Codes:

Some of the most common CPT administration codes for 'buy and bill' drugs can be found at the following link:

Potential NDC Listing Errors:

We have not identified any potential errors with the NDCs mapped to this HCPCS code.

About Byooviz:

BYOOVIZ is an Opthalmic Biosimilar drug manufactured by Biogen and administered via the Intraocular route of administration. The Q Code: Q5124 is aligned to the drug BYOOVIZ.

Byooviz is an injection into the eye that is used to treat certain eye disorders and diseases. This medication prevents the formation of new blood vessels under the retina. Byooviz is manufactured by Biogen and is a biosimilar to the medication Lucentis (J2778). This medication is currently aligned to the HCPCS code Q5124 and has been since April 2022. Patient assistance programs for this medication can be found through Biogen Biosimilar Support Services.

ACCESS PRICING AND MORE BY REGISTERING

Q5124 Added Date:

April 1, 2022

Q5124 Effective Date:

January 1, 2023

Q5124 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Byooviz billing and coding information.
Byooviz patient assistance information can be found through Biogen Biosimilar Support Services at the URL: https://www.byoovizhcp.com/support/index.html
BYOOVIZ prescribing information can be found at the link below:
Information regarding BYOOVIZ’s side effects can be found at MedlinePlus